Clinical Trial Update: A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating BHQ880 in combination with zoledronic acid in relapsed or refractory multiple myeloma with bone disease has completed. Sponsor: Novarti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BHQ880 (anti-DKK1 monoclonal antibody)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Myeloma Bone Disease | Phase 1 | Status: COMPLETED